![Peter Davies](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Peter Davies
Direktor/Vorstandsmitglied bei
Bionomics Ltd.
Vermögen: 24 596 $ am 30.09.2026
Profil
Mr. Peter M.
Davies is an Independent Non-Executive Director at Neuphoria Therapeutics, Inc., an Independent Non-Executive Director at Bionomics Ltd. and a Chief Business Officer at Leaf4life, Inc. He is on the Board of Directors at Neuphoria Therapeutics, Inc. and Bionomics Ltd. Mr. Davies was previously employed as a Managing Director by Apeiron Investment Group Ltd. He received his graduate degree from The University of Edinburgh.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
0.13% | 17.09.2026 | 6’909 ( 0.13% ) | 24 596 $ | 30.09.2026 |
Aktive Positionen von Peter Davies
| Unternehmen | Position | Beginn |
|---|---|---|
Bionomics Ltd.
 Bionomics Ltd. Pharmaceuticals: MajorHealth Technology Develops therapeutics for cancer and diseases of the central nervous system | Direktor/Vorstandsmitglied | 01.07.2021 |
Leaf4life, Inc.
 Leaf4life, Inc. Miscellaneous Commercial ServicesCommercial Services LEAF4Life specializes in developing medicines targeting hypoxia-related disorders. The private company is based in Woburn, MA. The company's lead product, LEAF-4L6715, is a proprietary liposomal formulation of transcrocetin aimed at enhancing oxygen diffusion in patients with conditions such as acute respiratory distress syndrome (ARDS), cancer, and cardiovascular diseases. | Corporate Officer/Principal | - |
Ehemalige bekannte Positionen von Peter Davies
| Unternehmen | Position | Ende |
|---|---|---|
Apeiron Investment Group Ltd.
 Apeiron Investment Group Ltd. Investment ManagersFinance Apeiron Investment Group invests in both public and private companies located across the globe primarily in the United States. The firm targets companies operating across a broad range of sectors and industries. It participates in pre-seed, seed, early, later and growth stage transactions. The firm invests in funds. It also acquires minority interest. | Private Equity Investor | 01.01.2022 |
Ausbildung von Peter Davies
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
18
Beziehungen ersten Grades
4
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 4 |
|---|---|
Bionomics Ltd.
Bionomics Ltd. Pharmaceuticals: MajorHealth Technology Develops therapeutics for cancer and diseases of the central nervous system | Health Technology |
The University of Edinburgh
 The University of Edinburgh Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Apeiron Investment Group Ltd.
Apeiron Investment Group Ltd. Investment ManagersFinance Apeiron Investment Group invests in both public and private companies located across the globe primarily in the United States. The firm targets companies operating across a broad range of sectors and industries. It participates in pre-seed, seed, early, later and growth stage transactions. The firm invests in funds. It also acquires minority interest. | Finance |
Leaf4life, Inc.
Leaf4life, Inc. Miscellaneous Commercial ServicesCommercial Services LEAF4Life specializes in developing medicines targeting hypoxia-related disorders. The private company is based in Woburn, MA. The company's lead product, LEAF-4L6715, is a proprietary liposomal formulation of transcrocetin aimed at enhancing oxygen diffusion in patients with conditions such as acute respiratory distress syndrome (ARDS), cancer, and cardiovascular diseases. | Commercial Services |
